Champions Oncology (CSBR) Share-based Compensation (2010 - 2026)
Champions Oncology (CSBR) posted quarterly Share-based Compensation of $357000.0 for Q2 2026, up 172.52% year-over-year from $131000.0 in Q2 2025, and down 15.6% quarter-over-quarter from $423000.0 in Q1 2026.
Champions Oncology (CSBR) Share-based Compensation (2010 - 2026) Analysis & Trends
Champions Oncology's Share-based Compensation history runs 17 years deep, the most recent figure standing at $357000.0 for Q2 2026.
- In Q2 2026, Share-based Compensation rose 172.52% year-over-year to $357000.0; the TTM figure through Apr 2026 stood at $1.2 million (up 89.14% YoY), while the FY2026 annual figure was $1.2 million, up 89.14% from the prior year.
- Share-based Compensation for Q2 2026 stood at $357000.0, down from $423000.0 in the prior quarter.
- The five-year high for Share-based Compensation was $423000.0 in Q3 2023, with the low at $9000.0 in Q4 2024.
- The 5-year median for Share-based Compensation is $252500.0 (2025), against an average of $242833.3.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation sank 91.64% in 2022, then soared 2666.67% in 2025.
- Champions Oncology's Share-based Compensation stood at $119000.0 in 2022, then tumbled by 55.46% to $53000.0 in 2023, then plunged by 83.02% to $9000.0 in 2024, then jumped by 2666.67% to $249000.0 in 2025, then surged by 43.37% to $357000.0 in 2026.
- Business Quant data shows CSBR's Share-based Compensation at $357000.0 in Q2 2026, $423000.0 in Q1 2026, and $249000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 357,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 357,000.00 |
| Apr 30, 2026 | 357,000.00 |
| Jan 31, 2026 | 423,000.00 |
| Jan 31, 2026 | 423,000.00 |
| Oct 31, 2025 | 249,000.00 |
| Oct 31, 2025 | 249,000.00 |
| Jul 31, 2025 | 208,000.00 |
| Jul 31, 2025 | 208,000.00 |
| Apr 30, 2025 | 131,000.00 |
| Apr 30, 2025 | 131,000.00 |
| Jan 31, 2025 | 256,000.00 |
| Jan 31, 2025 | 256,000.00 |
| Oct 31, 2024 | 9,000.00 |
| Oct 31, 2024 | 9,000.00 |
| Jul 31, 2024 | 258,000.00 |
| Jul 31, 2024 | 258,000.00 |
| Apr 30, 2024 | 263,000.00 |
| Apr 30, 2024 | 263,000.00 |
| Jan 31, 2024 | 379,000.00 |
| Jan 31, 2024 | 379,000.00 |